Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
A recent study found that 4 out of FIVE asthma patients who achieved control with Seretide maintained that control for a year. This reinforces Seretide's efficacy in managing asthma symptoms over an extended period. 4 in 5 patients with asthma who achieved control on SERETIDE sustained it at 1 year.1
STRATUM 2*
In stratum 2*, the study revealed a significant difference in the proportion of patients achieving an AQLQ score of 6 or higher 1:
IN FAVOR OF SERETIDE
The difference was statistically significant (p<0.001) for phase I and (p=0.008) for phase II, indicating a clear advantage for SERETIDE in this stratum.1
STRATUM 3*
Similarly, in stratum 3*, SERETIDE demonstrated superior efficacy1:
DIFFERENCE
In favor of SERETIDE
FP
Patients achieving AQLQ ≥ 6
SERETIDE
Patients achieving AQLQ ≥ 6
Again, the difference was statistically significant (p=0.005), reinforcing SERETIDE's effectiveness across different patient groups.1
CLINICAL IMPLICATIONS
These results suggest that SERETIDE offers superior asthma control compared to FP alone, as measured by AQLQ scores. The consistently higher proportion of patients achieving clinically significant improvements in quality of life indicates that SERETIDE may be a preferred treatment option for many asthma patients.1
CONCLUSION
The study provides strong evidence for the efficacy of SERETIDE in improving asthma-related quality of life. However, further research is needed to understand long-term outcomes, potential side effects, and cost-effectiveness. Healthcare providers should consider these findings when developing personalized asthma management plans.1
*Those who did not achieve at least two well-controlled weeks in the 4-week run-in period were randomized to one of three strata based on their inhaled corticosteroid dose during the 6 months before screening: stratum 1, no inhaled corticosteroid; stratum 2, 500 μg or less of beclomethasone dipropionate daily or equivalent; or stratum 3, more than 500 to 1,000 μg or less of beclomethasone dipropionate daily or equivalent.1
Seretide safety information:
Contraindications:
SERETIDE is contraindicated in patients with a history of hypersensitivity to any of the ingredients(For SERETIDE DISKUS is contraindicated in patients with severe milk-protein allergy.
Adverse events:
Very common: Headache
Common: Candidiasis of mouth and throat, pneumonia(in COPD patients), Hoarseness/dysphonia, Muscle cramps, arthralgia.
Abbreviation:
AQLQ, Asthma Quality of Life Questionnaire; FP, Fluticasone Propionate.
References:
[1] Bateman ED;American journal of respiratory and critical care medicine;2004;170;836-844.
GSK does not recommend, endorse or accept liability for sites controlled by a third party
SINA Guidelines
Asthma Control Test
Seretide Prescribing Information
Trademarks are owned by or licensed to the GSK group of companies
PM-SA-FPS-WCNT-250002 - Date of preparation: July 2025
